

SeQuent Scientific Limited
(Formerly known as P.I.DRUGS & PHARMACEUTICALS LTD)
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2010

(₹ In Millions)

Sr. No.	Particulars	STANDALONE		
		Quarter Ended	Quarter Ended	YEAR ENDED
		30.06.2010	30.06.2009	31.03.2010
		UNAUDITED	UNAUDITED	AUDITED
1	Net Sales / Income from Operations	627.48	516.45	2,483.35
	Total Revenue	627.48	516.45	2,463.35
2	Expenditure			
a	(Increase)/Decrease in stock in Trade and work in progress	(35.90)	(31.15)	(75.70)
b	Consumption of Raw Materials	260.73	227.82	1,081.53
c	Purchase of Traded Goods	97.20	4.16	31.60
d	Conversion charges	24.52	16.41	99.62
e	Employee Cost	58.70	45.91	202.05
f	Depreciation	31.22	33.41	125.22
g	Other Expenditure	127.64	119.77	523.45
h	Total	564.11	416.33	1,987.71
3	Profit from Operations before other income, interest and exceptional items.	63.37	100.12	475.64
4	Other Income	11.72	5.54	72.87
5	Profit before interest & exceptional items	75.09	105.66	548.51
6	Financial cost	40.96	46.78	187.32
7	Profit after interest but before exceptional items	34.13	58.88	361.19
8	Exceptional items	-	-	57.50
9	Profit from ordinary activities before tax	34.13	58.88	303.69
10	Tax Expense	7.80	11.57	95.76
11	Net Profit from Ordinary activities after Tax	26.33	47.31	207.93
12	Extraordinary items	-	-	-
13	Net Profit	26.33	47.31	207.93
14	Paid-up equity share capital (Face Value per share ₹ 10/each)	219.35	212.35	212.35
15	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	946.29
16	Earnings Per Share before Extraordinary Items for the period (Non-Annualised)			
	Basic (₹)	1.24*	2.23	9.79
	Diluted (₹)	1.24*	2.23	9.79
	Earnings Per Share after Extraordinary Items for the period (Non-Annualised)			
	Basic (₹)	1.24*	2.23	9.79
	Diluted (₹)	1.24*	2.23	9.79
17	Public Share Holding			
	No. of Shares	6,715,659	6,372,586	6,185,553
	% of Share Holding	30.62%	30.01%	29.13%
18	Promoters and Promoter Group Shareholding			
	a) Pledged / Encumbered			
	1. No of shares	Nil	Nil	Nil
	2. Percentage of shares(as a % of the total shareholding of promoter & promoter group)	NA	NA	NA
	3. Percentage of shares (as a % of the total share capital of the company)	NA	NA	NA
	b) Non-encumbered			
	1. No of shares	15,219,532	14,862,595	15,049,638
	2. Percentage of shares(as a % of the total shareholding of promoter & promoter group)	100%	100%	100%
	3. Percentage of shares (as a % of the total share capital of the company)	69.38%	69.99%	70.87%

* For Calculation purposes, shares allotted to Employee Stock Option Plan Trust have not been considered.

Notes:

- The unaudited financial results were taken on record by the Board of Directors at its meeting held on August 13, 2010.
The statutory auditors have performed a limited review of the standalone financial results for the quarter ended as on June 30th, 2010
- Exceptional items for the year ended March 31, 2010, consist of management estimate of impairment loss of ₹ 57.5 million in investments made in Galénica BV, where the Company now holds 50.25% in Galénica together with its subsidiary Sequent Global Holdings Limited.
- The company has decided to merge its 100% subsidiary, M/s Vedic Elements Private Ltd, with w.e.f. October 1, 2009, which is pending approval of Hon'ble HighCourt of Karnataka.
- Consequent to the merger of erstwhile Sequent Scientific Limited with the Company, figures for the quarter ended 30 June 2009 have been recasted to give effect to the scheme of amalgamation. These recasted figures are neither audited nor reviewed by the auditors
- Details of investor complaints for the quarter ended 30th June 2010:

Unresolved at the beginning of the quarter :	Nil
Received during the quarter :	Nil
Disposed of during the quarter :	Nil
Unresolved at the end of quarter :	Nil

6. Segment Results

The company has identified Pharmaceuticals and Speciality Chemicals as its business segments, Segments have been identified taking in to account the nature of services, the differing risks & returns, the organisational structure & the internal reporting system.

Segment wise Revenue, Results and Capital Employed:

SI No	Particulars	(₹ in Millions)		
		Quarter ended 30.06.2010 (Unaudited)	Quarter ended 30.06.2009 (Unaudited)	Year ended 31.03.2010 (Audited)
1	Segment Revenue			
	a) Pharmaceuticals	532.05	394.25	1,915.54
	b) Speciality Chemicals	106.11	123.74	596.14
	Total	637.16	517.99	2,511.68
	Less Intersegment Revenue	9.68	1.54	48.33
	Add other un allocated Income			-
	Net Sales /Income from Operations	627.48	516.45	2,463.35
2	Segment Results			
	Profit or Loss before Tax and Interest from Each Segment			
	a) Pharmaceuticals	64.97	64.60	378.19
	b) Speciality Chemicals	28.67	50.94	197.02
	Total	93.64	115.54	575.21
	Less (i) Finance Cost	40.96	46.78	187.31
	(ii) other unallocable expenditure net off unallocable income	18.55	9.88	84.21
	Total Profit Before Tax	34.13	58.88	303.69
3	Capital Employed			
	a) Pharmaceuticals	3,110.02	3,278.40	2,974.29
	b) Specialty Chemicals	344.50	346.68	329.07
	c) Unallocated	(854.81)	(934.99)	(680.11)
	Total	2,899.71	2,690.09	2,613.25

- Figures for previous periods may have been regrouped and rearranged, wherever necessary, to conform to the relevant current Period classification.

For Sequent Scientific Limited

Place :Bangalore

Date:- August 13, 2010

K.R.Ravishankar
Chairman & Managing Director